Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
J Cancer
2016 Oct 25;715:2207-2212. doi: 10.7150/jca.16768.
Show Gene links
Show Anatomy links
Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population.
Zaric B
,
Stojsic V
,
Panjkovic M
,
Tegeltija D
,
Stepanov V
,
Kovacevic T
,
Sarcev T
,
Radosavljevic D
,
Milovancev A
,
Adamidis V
,
Zarogoulidis P
,
Hohenforst-Schmidt W
,
Trakada G
,
Rapti A
,
Perin B
.
???displayArticle.abstract???
Introduction: The incidence of echinoderm microtubule-associated protein-like4-anaplastic lymphoma kinase (EML4-ALK) mutation among surgically treated patients with adenocarcinoma of the lung of the Eastern European ethnicity is underreported. The aim of this trial was the determination of EML4-ALK mutation frequency in investigated population, and the evaluation of correlations between lung adenocarcinoma subtype and clinical characteristics with mutation status. Patients and methods: This was a prospective trial which included 195 patients with adenocarcinoma of the lung who underwent surgical treatment. ALK mutation screening was performed by immunohistochemistry (IHC). IHC scores of 2+ and 3+ were regarded as positive. Confirmatory FISH was performed in all IHC positive and in 2:1 ratio in negative patients. Results: Overall ALK mutation rate established by IHC was 6.2%, while FISH confirmed rate of 5.1%. The FISH confirmed ALK positivity in 7.6% Hungarians, 5.5% Serbians, and 6.6% Slovakians. Acinar subtype of adenocarcinoma of the lung was significantly (p=0.02) related to EML4-ALK positive mutation status. Most of the patients were males (56.9%), smokers (50.8%), or former smokers (28.7%) with acinar (55.4%) or solid (35.9%) adenocarcinoma of the lung. Sensitivity and specificity of IHC were 100% and 98.9% respectively. Conclusions: ALK mutation rate in surgically treated patients with adenocarcinoma of the lung was found to be 6.2% by IHC and 5.1% by FISH. Acinar subtype of the adenocarcinoma of the lung was significantly related to ALK positive mutation.
???displayArticle.pubmedLink???
27994656
???displayArticle.pmcLink???PMC5166529 ???displayArticle.link???J Cancer
Blackhall,
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
2014, Pubmed
Blackhall,
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
2014,
Pubmed
Fan,
Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.
2014,
Pubmed
Hu,
Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma.
2014,
Pubmed
Kim,
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
2014,
Pubmed
Korpanty,
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.
2014,
Pubmed
Leighl,
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
2014,
Pubmed
Pan,
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
2014,
Pubmed
Park,
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
2012,
Pubmed
Peters,
Treatment and detection of ALK-rearranged NSCLC.
2013,
Pubmed
Sun,
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
2014,
Pubmed
Wang,
Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.
2014,
Pubmed
Ye,
Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old.
2014,
Pubmed
Zhou,
Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening.
2014,
Pubmed